SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Innovent Biologics, Inc. (IVBXF) trades at a trailing P/E of 22.9, forward P/E of 7.4. Trailing earnings yield is 4.36%, forward earnings yield 13.59%. PEG 0.03 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (75/100, Pass) — P/E is below market average (22.9); PEG ≤ 1.0 — Peter Lynch undervalued (0.03); earnings yield beats bond yields (4.36%).
- Forward P/E 7.4 (down from trailing 22.9) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.03 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 4.36% — roughly competitive with bond yields (~4.3%), moderate risk-reward. Forward yield improves to 13.59% as earnings recover.
Overall SharesGrow Score: 69/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
75/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — IVBXF
Valuation Multiples
P/E (TTM)22.9
Forward P/E7.4
PEG Ratio0.03
Forward PEG0.03
P/B Ratio0.00
P/S Ratio1.45
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.46
Forward EPS (Est.)$1.43
Book Value / Share$0.00
Revenue / Share$7.30
FCF / Share$0.00
Yields & Fair Value
Earnings Yield4.36%
Forward Earnings Yield13.59%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-0.45 |
$32.13M |
$-504.2M |
-1569.4% |
| 2017 |
$-0.50 |
$18.54M |
$-562.32M |
-3033.3% |
| 2018 |
$-17.24 |
$9.48M |
$-5.77B |
-60900% |
| 2019 |
$-1.51 |
$1.05B |
$-1.78B |
-169.6% |
| 2020 |
$-0.74 |
$3.84B |
$-998.42M |
-26% |
| 2021 |
$-2.16 |
$4.27B |
$-3.14B |
-73.5% |
| 2022 |
$-1.46 |
$4.56B |
$-2.18B |
-47.8% |
| 2023 |
$-0.66 |
$6.21B |
$-1.03B |
-16.6% |
| 2024 |
$-0.06 |
$9.42B |
$-94.63M |
-1% |
| 2025 |
$0.46 |
$12.7B |
$792.57M |
6.2% |
